Research at Oslo University Hospital

The Malmberg Lab at the Department of Cancer Immunology, Institute for Cancer Research, OUH and the Institute for Clinical Medicine, UiO, reports a systems-level immune profiling in patients with diffuse large-B cell lymphoma (DLBCL). The paper is published online in Med, a new flagship medical journal from Cell Press. 
DLBCL is the most common form of lymphoma. Despite advances in treatment, there are still large differences in outcome that are not fully explained by current clinical variables. 

The Publish and Read agreements make it possible for researchers to publish openly and at the same time completely free of charge. The Open Access team at the University of Oslo Library answers the researchers most frequently asked questions.

Join the digital presentation "OA publisering og lisenser" on Tuesday, December 8, 2020, at 3:00 PM on Skype for Business. The presentation will be held by Ivana Malovic and Daniel Kalvø, the target group is researchers at OUS and the language is Norwegian. No registration, follow the Skype link to the event.

IMPRESS-Norway, a large national study on precision medicine against cancer, starts in the beginning of 2021. 
During 2019, Oslo Cancer Cluster hosted a series of workshops with public and private stakeholders in cancer. The joint goal was to accelerate the implementation of cancer precision medicine in Norway. The initial idea for IMPRESS emerged in one of these workshops. A dedicated team, including Kjetil Taskén, Sigbjørn Smeland, Åslaug Helland and Hege Russnes, at Oslo University Hospital quickly turned it into a national effort together with colleagues at university hospitals across Norway.

Cancer researcher and scientist Caroline Nunes-Xavier from the Department of Tumor Biology at the Institute for Cancer Research (OUS) since 2013, receives a prestigious grant from the Spanish Ministry of Science and Innovation, called Contratos Miguel Servet. This is a 5-year funding for her as a young independent researcher, with a potential prolongation of 5 years and a commitment for a permanent position. 

Professor Johanna Olweus from the Department of Cancer Immunology was in 2019 awarded the ERC Consolidator Grant of 20 mill NOK for the immunotherapy project "OUTSOURCE: Outsourcing cancer immunity to healthy donors". 
The OUTSOURCE project has just started, and on that occacsion Olweus has recently been interviewed by the UiO magazine Apollon on how her group of 15 over the next five years will take their research a long step further towards the clinic, how immune cells from healthy individuals can be the new immune cure for cancer, and how this treatment can kill cancer cells without destroying neighbouring cells. 

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.

Dr. Theo Theodossiou at Department of Radiation Biology, Institute for Cancer Research, received Dr. Ragnar Mørk´s Prize for excellent cancer research in the auditorium of Institute for Cancer Research. Theodossiou received the prize for his research on photosensitizers in selective killing of cancer cells. His innovative research includes luminescence-based photosensitizer activation for killing of brain tumours, and proton-induced photosensitizer activation (proton-dynamic therapy) as a novel way of combining proton therapy with photodynamic therapy.

The Covid-19 pandemic has highlighted the need for rapid and safe testing of agents to treat a high number of SARS-CoV2 infected patients globally. Oslo University Hospital will, together with The Norwegian Institute for Public Health, take part in an ambitious European initiative sponsored by the EU. The project seeks to develop a common platform for clinical trials drawing on expertise from leading hospitals, universities, and research institutions across Europe.